City Therapeutics, Inc. priced its initial public offering at $18.00 a share, offering 11,111,111 shares of common stock, to list on the Nasdaq Global Market under the symbol CTY. It filed a Form S-1 registration statement for an initial public offering on September 24, 2026. As of November 8, 2026, its final prospectus is on file (Form 424B4, October 16, 2026).
Who owns City Therapeutics, Inc.?
Sell to companies like City Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
City Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-09-24. It has amended it 1 time. It filed its final prospectus on 2026-10-16, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for City Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 14% of the class | 5%+ stakes | Source |
| October 26, 2026 | Stake report, Schedule 13D, by ARCH Venture Fund XII, L.P. | 25.6% of the class | 5%+ stakes | Source |
| October 26, 2026 | Stake report, Schedule 13G, by VIKING GLOBAL INVESTORS LP | 7% of the class | 5%+ stakes | Source |
| October 22, 2026 | Stake report, Schedule 13G, by Invus Public Equities, L.P. | 8.1% of the class | 5%+ stakes | Source |
Check before you invest in City Therapeutics, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on City Therapeutics, Inc. and the records around it.
City Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- ARCH Venture Fund XII, L.P. also filed stake reports on 5 other companies: Parabilis Medicines, Inc. (Aug 2026), Seaport Therapeutics, Inc. (May 2026), Neumora Therapeutics, Inc. (Apr 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026), enGene Holdings Inc. (Aug 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026), Inhibrx Biosciences, Inc. (Aug 2026)
Also filing to list on the Nasdaq Global Market
IPO filings on the Nasdaq Global Market in Q4 2026, newest first.
- FireFly Robotics, Inc. (Oct 2026)
- Our Bond, Inc. (Oct 2026)
Watch City Therapeutics, Inc.
Get an email when City Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on City Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on City Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on City Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Market under the symbol “CTY.”From the 424B4 filed 2026-10-16
Shares offered
This is an initial public offering of shares of common stock of City Therapeutics, Inc. We are offering 11,111,111 shares of our common stock.From the 424B4 filed 2026-10-16
Offering price
The initial public offering price per share is $18.00.From the 424B4 filed 2026-10-16
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: approximately $30.0 million to fund the clinical development of CITY-FXI, including our ongoing Phase 1 clinical trial and the initiation of a Phase 2 TKA study; approximately $20.0 million to fund the clinical development of CITY-RBP4, including our Phase 1 clinical trial and preparations for later-stage clinical development for the treatment of Stargardt disease and GA; approximately $40.0 million to fund the clinical development of CITY-TFR2, including an IIT in China and the Phase 1/2 clinical trial, both focused on the treatment of anemia associated with…From the 424B4 filed 2026-10-16
Net loss or income
We have incurred significant net losses since our inception, including net losses of $27.8 million and $58.5 million for the years ended December 31, 2024 and 2025, respectively, and $24.3 million and $53.4 million for the six months ended June 30, 2025 and 2026, respectively.From the S-1/A filed 2026-10-09
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-09-24 | Registration statement filed | S-1 |
| 2026-10-09 | Registration statement amended | S-1/A |
| 2026-10-16 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for City Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.